Australia - English - Department of Health (Therapeutic Goods Administration)

innovatio dental supplies pty ltd - 35857 - dental alloy, casting, non-noble - this is a non noble dental alloy that is intended to be used for the prefabrication of dental restorations.

Australia - English - Department of Health (Therapeutic Goods Administration)

innovatio dental supplies pty ltd - 16187 - dental ceramic - this is a ceramic based blank that is inteded to be used for the prefabrication of dental restorations such as inlays, onlays, teeth, metal-ceramic crowns and bridges.

Australia - English - Department of Health (Therapeutic Goods Administration)

gc australasia dental pty ltd - 16187 - dental ceramic - dental ceramic powders are intended for use by professional dental technicians for the veneering of zirconium, titanium and various metal frameworks as well as without framework material such as veneers or as layered inlay. it is used by the dental technician with a ceramic brush. dental ceramics as press pellets are pressed into single-tooth restorations in dental ceramic press furnaces the indication extends to multi-unit restorations when zircon or metal is over-pressed as a framework material.

Australia - English - Department of Health (Therapeutic Goods Administration)

gc australasia dental pty ltd - 38643 - artificial teeth, resin - acrylic teeth for the production of dental restorations in form of long-term implants, provisional, acrylic veneers as well as removable dentures

Singapore - English - HSA (Health Sciences Authority)

ge healthcare pte. ltd. - sodium iodide [i-131] - injection - 74 mbq/ml - sodium iodide [i-131] 74 mbq/ml

Singapore - English - HSA (Health Sciences Authority)

ge healthcare pte. ltd. - sodium iodide [i-131] - injection - 925 mbq/ml - sodium iodide [i-131] 925 mbq/ml

United States - English - NLM (National Library of Medicine)

stat rx usa - benazepril hydrochloride (unii: n1sn99t69t) (benazeprilat - unii:jrm708l703) - benazepril hydrochloride 10 mg - benazepril hydrochloride is indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. in using benazepril hydrochloride, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. available data are insufficient to show that benazepril hydrochloride does not have a similar risk (see warnings). black patients receiving ace-inhibitors have been reported to have a higher incidence of angioedema compared to nonblacks. it should also be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks benazepril hydrochloride is contraindicated in patients who are hypersensitive to this product or to any other ace inhibitor.

United States - English - NLM (National Library of Medicine)

blenheim pharmacal, inc. - benazepril hydrochloride (unii: n1sn99t69t) (benazeprilat - unii:jrm708l703) - benazepril hydrochloride 40 mg - benazepril hydrochloride tablets, usp are indicated for the treatment of hypertension. benazepril hydrochloride tablets may be used alone or in combination with thiazide diuretics. in using benazepril consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. available data are insufficient to show that benazepril hydrochloride tablets do not have a similar risk (see warnings). black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to nonblacks. it should also be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks. benazepril hydrochloride tablets are contraindicated in patients who are hypersensitive to this product or to any other ace inhibitor. benazepril hydrochloride tablets are also contraindicated in patients with

United States - English - NLM (National Library of Medicine)

legacy pharmaceutical packaging, llc - hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th), lisinopril (unii: e7199s1ywr) (lisinopril anhydrous - unii:7q3p4bs2fd) - hydrochlorothiazide 12.5 mg - lisinopril and hydrochlorothiazide tablets usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmhg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (eg., on angina, heart failure, or diabetic kidney disease). these considerations may guide selection of therapy. these fixed-dose combinations are not indicated for initial therapy (see dosage and administration ). in using lisinopril and hydrochlorothiazide tablets usp, consideration should be given to the fact that an angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk. (see warnings ). in considering the use of lisinopril and hydrochlorothiazide tablets usp, it should be noted that ace inhibitors have been associated with a higher rate of angioedema in black than in nonblack patients. (see warnings , lisinopril ). lisinopril and hydrochlorothiazide is contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an angiotensin-converting enzyme inhibitor and in patients with hereditary or idiopathic angioedema. because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs. lisinopril and hydrochlorothiazide is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). do not administer lisinopril and hydrochlorothiazide tablets usp within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see warnings ). do not co-administer aliskiren with lisinopril and hydrochlorothiazide in patients with diabetes (see precautions, drug interactions ).

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - benazepril hydrochloride (unii: n1sn99t69t) (benazeprilat - unii:jrm708l703) - benazepril hydrochloride 5.00 mg - benazepril hydrochloride tablets, usp are indicated for the treatment of hypertension. benazepril hydrochloride tablets may be used alone or in combination with thiazide diuretics. in using benazepril consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. available data are insufficient to show that benazepril hydrochloride tablets do not have a similar risk (see warnings). black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to nonblacks. it should also be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks. benazepril hydrochloride tablets are contraindicated in patients who are hypersensitive to this product or to any other ace inhibitor. benazepril hydrochloride tablets are also contraindicated in patients with